Prognosis
Pfizer Vaccine Deal at $20 a Dose Sets Ceiling for Rivals
- U.S. agrees to pay Pfizer, BioNTech $1.95 billion on approval
- Government commits to securing an initial 100 million doses
This article is for subscribers only.
In signing a $2 billion deal to supply their experimental coronavirus vaccine to the U.S., Pfizer Inc. and BioNTech SE are setting a price ceiling of less than $20 a dose that will impact how much other companies can charge to protect people from Covid-19.
Pfizer’s $19.50 price-point takes into account the “public health requirements during the pandemic,” said Sally Beatty, a Pfizer spokeswoman. The companies are pursuing a two-dose regimen of one of its vaccine candidates, and the roughly $40 course, Beatty said, is “almost 30% less than what others charge for a seasonal flu vaccine.”